Parkinson’s disease (PD) is a progressive neurodegenerative disease characterized by dopaminergic neuronal loss and
α-synuclein (α-syn) aggregation. With the acceleration of population aging process, the incidence of PD is expected to
increase, putting a heavy burden on the whole society. Recent studies have found the alterations of gut microbiota (GM) in
PD patients and the clinical relevance of these changes, indicating the underlying relationship between GM and PD.
Additionally, elevated inflammatory responses originating from the gut play a crucial role in the initiation and progression of
PD, which is closely associated with GM. In this review, we will summarize recent studies on the correlation between GM
and PD, and discuss the possible pathogenesis of PD mediated by GM and subsequent inflammatory cascades. We will also
focus on the promising GM-based therapeutic strategies of PD, including antibiotics, probiotics and/or prebiotics, fecal
microbiota transplantation, and dietary interventions, aiming to provide some new therapeutic insights for PD. CLICK TO REVIEW
Keywords
Parkinson’s disease, gut microbiota, inflammation, α-synuclein, short chain fatty acids